Valneva submits adolescent label extension application for its chikungunya vaccine, ixchiq®, to uk mhra

Saint herblain (france), march 31, 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that it has submitted a label extension application to the medicines and healthcare products regulatory agency (mhra) of the united kingdom (uk) to potentially expand the use of its chikungunya vaccine, ixchiq®, currently approved in adults1, to adolescents aged 12 to 17 years in the uk. this submission follows the recent positive opinion of the european medicines agency (ema) on extension of ixchiq® label to adolescents in the european union (eu)2.
VALN Ratings Summary
VALN Quant Ranking